Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis

被引:52
作者
Sanchez Munoz-Torrero, Juan Francisco [2 ]
Bounameaux, Henri [3 ]
Maria Pedrajas, Jose [4 ]
Lorenzo, Alicia [5 ]
Rubio, Silvino [6 ]
Kearon, Clive [7 ]
Hernandez, Luis [8 ]
Monreal, Manuel [1 ]
机构
[1] Hosp Univ Germans Trias i Pujol, Med Interna Serv, Badalona 08916, Barcelona, Spain
[2] Hosp San Pedro de Alcantara, Med Interna Serv, Caceres, Spain
[3] Univ Hosp Geneva & Fac Med, Div Angiol & Haemostasis, Geneva, Switzerland
[4] Hosp Clin San Carlos, Med Interna Serv, Madrid, Spain
[5] Hosp Univ La Paz, Med Interna Serv, Madrid, Spain
[6] Hosp Cabuenes, Med Interna Serv, Gijon, Asturias, Spain
[7] McMaster Univ, Hamilton, ON, Canada
[8] Hosp Univ Alicante, Serv Neumol, Alicante, Spain
关键词
ORAL ANTICOAGULANT-THERAPY; INTENSITY WARFARIN THERAPY; VENOUS THROMBOEMBOLISM; LONG-TERM; PREVENTION; HEPARIN;
D O I
10.1016/j.jvs.2011.05.114
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The risk of patients dying of pulmonary embolism (PE) or bleeding during the treatment of deep vein thrombosis (DVT), and whether these risks are influenced by patient age, has not been thoroughly studied. Methods: We used data from the Registro Informatizado de la Enfermedad TromboEmbolica (RIETE) to assess the risk of fatal PE and fatal bleeding in 16,199 patients with lower limb DVT (without symptomatic PE at the time of inclusion) during the 3 months after diagnosis, with patients categorized according to age. Results: During the 3 months of anticoagulant treatment, there were 31 fatal PEs (0.19%) and 83 fatal hemorrhages (0.51%). During the first 7 days of therapy, the frequency of fatal PEs was similar to that of fatal bleeding (12 vs 14 deaths, respectively; odds ratio [OR], 0.86; 95% confidence interval [CI], 0.39-1.87). However, from days 8 to 90, the frequency of fatal bleeding was greater than that of fatal PE (69 vs 19 deaths; OR, 3.64; 95% CI, 2.22-6.20). The higher frequency of fatal bleeding compared with fatal PE from days 8 to 90 appeared to be confined to patients who were aged >= 60 years. Multivariate analysis showed that patient age was independently associated with an increased risk of death from bleeding during the first 3 months: every 10 years the OR increased by 1.37 (95% CI, 1.12-1.67). Conclusions: During the first week of treatment, the risk of fatal bleeding and fatal PE were similar. Then, particularly in patients who were aged >= 60 years, the risk of dying from bleeding exceeded the risk of dying from PE. (J Vase Surg 2011;54:26S-325.)
引用
收藏
页码:26S / 33S
页数:8
相关论文
共 17 条
[1]   The management and outcome of acute venous thromboembolism:: A prospective registry including 4011 patients [J].
Arcelus, JI ;
Caprini, JA ;
Monreal, M ;
Suárez, C ;
González-Fajardo, J .
JOURNAL OF VASCULAR SURGERY, 2003, 38 (05) :916-922
[2]   Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism [J].
Carrier, Marc ;
Le Gal, Gregoire ;
Wells, Philip S. ;
Rodger, Marc A. .
ANNALS OF INTERNAL MEDICINE, 2010, 152 (09) :578-+
[3]  
HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602
[4]   Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism [J].
Kearon, C ;
Ginsberg, JS ;
Kovacs, MJ ;
Anderson, DR ;
Wells, P ;
Julian, JA ;
MacKinnon, B ;
Weitz, JI ;
Crowther, MA ;
Dolan, S ;
Turpie, AG ;
Geerts, W ;
Solymoss, S ;
van Nguyen, P ;
Demers, C ;
Kahn, SR ;
Kassis, J ;
Rodger, M ;
Hambleton, J ;
Gent, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07) :631-639
[5]   Antithrombotic therapy for venous thromboembolic disease [J].
Kearon, Clive ;
Kahn, Susan R. ;
Agnelli, Giancarlo ;
Goldhaber, Samuel ;
Raskob, Gary E. ;
Comerota, Anthony J. .
CHEST, 2008, 133 (06) :454S-545S
[6]   Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism [J].
Kearon, Clive ;
Ginsberg, Jeffrey S. ;
Julian, Jim A. ;
Douketis, James ;
Solymoss, Susan ;
Ockelford, Paul ;
Jackson, Sharon ;
Turpie, Alexander G. ;
MacKinnon, Betsy ;
Hirsh, Jack ;
Gent, Michael .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (08) :935-942
[7]  
LAGERSTEDT CI, 1985, LANCET, V2, P515
[8]   Clinical predictors for fatal pulmonary embolism in 15 520 patients with venous thromboembolism -: Findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) registry [J].
Laporte, Silvy ;
Mismetti, Patrick ;
Decousus, Herve ;
Uresandi, Fernando ;
Otero, Remedios ;
Lobo, Jose Luis ;
Monreal, Manuel .
CIRCULATION, 2008, 117 (13) :1711-1716
[9]  
LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606
[10]   Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism - A meta-analysis [J].
Linkins, LA ;
Choi, PT ;
Douketis, JD .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (11) :893-900